0001209191-18-010536.txt : 20180215
0001209191-18-010536.hdr.sgml : 20180215
20180215193132
ACCESSION NUMBER: 0001209191-18-010536
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180212
FILED AS OF DATE: 20180215
DATE AS OF CHANGE: 20180215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Azelby Robert
CENTRAL INDEX KEY: 0001656998
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36781
FILM NUMBER: 18619282
MAIL ADDRESS:
STREET 1: 307 WESTLAKE AVE. NORTH, STE 300
CITY: SEATTLE
STATE: WA
ZIP: 98109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Juno Therapeutics, Inc.
CENTRAL INDEX KEY: 0001594864
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 463656275
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 2065821600
MAIL ADDRESS:
STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200
CITY: SEATTLE
STATE: WA
ZIP: 98109
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2018-02-12
2018-02-14
0
0001594864
Juno Therapeutics, Inc.
JUNO
0001656998
Azelby Robert
C/O 400 DEXTER AVENUE NORTH
SUITE 1200
SEATTLE
WA
98109
0
1
0
0
EVP & Chief Commercial Officer
Common Stock
2018-02-12
4
S
0
4159
85.55
D
89612
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017.
This Amendment to Form 4 is filed solely for the purpose of correcting a clerical error in the number of shares sold, as reported on the Form 4 filed February 14, 2018.
/s/ Zachary D. Hale, attorney-in-fact
2018-02-15